Normal scar tissue forms to heal an internal wound and quietly retreats when the job is done. But in many common diseases — kidney, liver and lung fibrosis — the scar tissue goes rogue and strangles vital organs. These diseases are largely untreatable and ultimately fatal.
A new Northwestern Medicine study has newly identified a trigger of some fibrotic diseases and an experimental compound to treat it.
Fibrosis — a progressive scarring and hardening of internal organs — is estimated to cause 35 to 40 percent of deaths in the world. Fibrotic diseases include diabetic kidney fibrosis, alcoholic liver cirrhosis, hepatitis C, pulmonary fibrosis and nonalcoholic fatty liver disease, which may lead to fibrosis of the liver, the leading cause of liver transplant.
In one subset of human fibrosis cells, scientists discovered a delinquent gang of molecules that continually shouted at an immune receptor — the antennae on the cell — to produce scar tissue instead of quieting down and allowing the scar tissue to go back to sleep.
Scientists collaborated with a University of Colorado researcher who used crystallography and computer modeling to predict a molecule that could block the receptor that leads to the uncontrolled scarring. When they tested the molecule, T53, in three different mouse models of fibrosis, the abnormality was significantly reversed.
“Our study opens a new door into fibrosis by looking at it as an aberrant innate immune response and suggesting a novel approach to treat it,” said senior author Dr. John Varga, director of the Northwestern Scleroderma Program and the John and Nancy Hughes Distinguished Professor of Rheumatology at Northwestern University Feinberg School of Medicine.
The paper was published July 12 in the Journal of Clinical Investigation Insight.
“The leading cause of liver failure in western world is obesity and that’s because of liver fibrosis,” Varga said. “In the U.S., many of these diseases are lifestyle or age dependent. As we get fatter or older, they get worse.”
Most fibrotic disease likely begins as normal repair of an injury, scientists said. “But if the immune system produces too much of an initial scar, it can’t go back to normal,” Varga said. “You have an unhealed scar that keeps growing and can wipe out the entire organ.”
Not everyone’s fibrosis is caused by the same abnormality, Varga said. If the compound, T53, is eventually developed into an approved drug, it would be targeted to patients with the specific genetic signature identified in the study.
“There is an emerging direction for treating fibrosis with precision medicine,” said first author Swati Bhattacharyya, research associate professor of medicine in rheumatology and scientific director of the Scleroderma Research Laboratory at Feinberg. “Some people live with fibrotic disease for 30 years while others die in two years. We need to identify the rapid progressors from the slow progressors. That’s where precision medicine becomes really critical.”
“The results of this study are encouraging,” Varga said. “We are not saying this compound is ready to be a drug. It’s an initial compound that would need to be developed and tweaked. It would need significant funding to go to the next step.”
Learn more: Why internal scars won’t stop growing
The Latest on: Fibrosis
[google_news title=”” keyword=”fibrosis” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
via Google News
The Latest on: Fibrosis
- R400k boost for cystic fibrosis fighterson May 9, 2024 at 3:35 am
Breathtaking Fundraising, a non-profit that supports individuals with cystic fibrosis in South Africa, has received a R400,000 donation to address the significant challenge of medication ...
- Researchers outline how cells activate to cause fibrosis and organ scarringon May 8, 2024 at 7:16 am
New research led by Unity Health Toronto that examines how fibroblast cells in the body are activated to cause fibrosis and organ scarring has been published in Nature Reviews Molecular Cell Biology.
- 3 cousins traveling US Route 66 for Cystic Fibrosis awareness make stop in Amarilloon May 8, 2024 at 5:08 am
Three cousins traveling US Route 66 to raise awareness and funding for Cystic Fibrosis Awareness Month will drive through Amarillo in classic cars on Wednesday.
- Butte Calcutta raises more than $42,000 for Cystic Fibrosis supporton May 7, 2024 at 11:56 am
Organizers say the 10th annual Butte Cystic Fibrosis NCAA March Madness Calcutta was once again a success, raising $34,785 for the Cystic Fibrosis Foundation and another $8,500 for the Cody Dieruf ...
- Cystic Fibrosis Community Perspectives Influence Future of CF Care Modelon May 7, 2024 at 6:48 am
The Cystic Fibrosis Foundation conducted a national survey of people with cystic fibrosis, families, and clinicians to understand how CF care centers can adapt to meet the changing needs of people ...
- Vertex files FDA approval ask for next-gen cystic fibrosis candidate, resumes diabetes cell therapy trialon May 7, 2024 at 4:30 am
Vertex Pharmaceuticals is ahead of schedule, filing a new drug application for its next-gen cystic fibrosis (CF) treatment dubbed vanza triple. Vertex completed the regulatory submission a month ...
- Vertex Pharmaceuticals 1Q Sales Up 13% on Cystic Fibrosis Drugon May 6, 2024 at 1:22 pm
By Paul Ziobro Vertex Pharmaceuticals posted double-digit sales growth in the first-quarter, topping Wall Street expectations, on continued growth of ...
- Vertex tops Q1 profit estimates on robust demand for cystic fibrosis treatmentson May 6, 2024 at 1:11 pm
Vertex Pharmaceuticals beat Wall Street estimates for first-quarter profit on Monday, driven by robust uptake for its cystic fibrosis treatments. Cystic fibrosis (CF) - an inherited disorder that ...
- Parents of Infants With Cystic Fibrosis Often Feel Confused, Unsupported: Surveyon May 6, 2024 at 3:07 am
Parents of newborns often don’t understand early screening tests for disease like cystic fibrosis. Three out of four parents whose child had a positive newborn sc ...
via Bing News